

Pyrazinamide resistance in MDR and extensively drug-resistant tuberculosis.

Lan Yao, Qing Zhang, Yidan Liu, Heping Xiao*

Tuberculosis Center for Diagnosis and Treatment, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China

Abstract

Background: Pyrazinamide (PZA) is an important first-line antituberculosis drug in drug resistant and drug sensitive regimen. Incorporation of pyrazinamide into the first-line regimen had made it possible to reduce the treatment duration to six months. But drug resistant rate of PZA is high in MDR and XDR tuberculosis.

Methods: We reviewed a phase II clinical trial in our hospital to identify the clinical characteristics of PZA resistant tuberculosis.

Results: In our study, the mean time of anti-tuberculosis treatment before enrolled in the study was 2.6 ± 3.1 years in the PZA resistant (PZA^r) group and 2.3 ± 1.4 years in the PZA sensitive (PZA^s) group. The mean time of using PZA prior to the study in PZA^r group and PZA^s group were 1.1 ± 2.0 years and 0.5 ± 0.3 years respectively. The rate of PZA resistance was 80% (16/20) in MDR-TB and 100% (7/7) in XDR-TB.

Conclusions: So whether to use PZA in MDR or XDR tuberculosis regimen still needs be identified.

Keywords: Tuberculosis, Pyrazinamide resistant, Multidrug resistance, MDR/XDR-TB.

Accepted on December 29, 2016

Introduction

Pyrazinamide is an antituberculosis drug which can be dated back to 1950s. It has been estimated that pyrazinamide works by binding the ribosomal protein S1 and then inhibits the trans-translation [1]. PZA plays a central role in antituberculosis chemotherapy by making it possible to reduce the first-line treatment duration to six months in combination with isoniazid and rifampin [2]. But there is the emergence of pyrazinamide resistant strains threatening the public health, as pyrazinamide is important in both first and second-line treatment regimens [3]. WHO recommends pyrazinamide be included in the intensive phase with a fluoroquinolone, a parenteral agent, ethionamide (or prothionamide), and cycloserine, or else para-aminosalicylic acid if cycloserine cannot be used in the treatment of patients with Multi-drug-resistant tuberculosis (MDR-TB) in 2011 [4]. In recent edition of guidelines for drug-resistant tuberculosis by WHO, PZA is still recommended in the intensive phase unless there is confirmed resistance from reliable DST (WHO treatment guidelines for drug-resistant tuberculosis. 2016 update (WHO/HTM/TB/2016.04). Geneva, World Health Organization. But the recent study showed that of all the MDR strains, 69.0% (40/58) were PZA resistant [5]. To further understand the clinical characteristics of pyrazinamide resistance in MDR/XDR tuberculosis, we reviewed a phase II clinical trial in Shanghai Pulmonary Hospital.

Materials and Methods

Patient recruitment

38 MDR-TB patients were recruited in Shanghai pulmonary hospital for a phase II global multi-center trial to evaluate the safety, efficacy, and pharmacokinetics of multiple doses of delamanid (Trial 204). The 38 patients were randomly assigned to different treatment groups. Inclusion criteria were: 1) written, informed consent; 2) male or female aged between 18 and 64 years; 3) either mycobacterial culture of sputum positive for growth or sputum smear positive for acid-fast bacilli with a positive rapid test for rifampicin resistance on direct sputum, 60 days before the expected date of enrolment; 4) patients with TB caused by isolates of *M. tuberculosis* complex confirmed to be resistant to isoniazid and rifampicin; 5) findings on chest radiograph consistent with TB; 6) able to produce sputum for mycobacterial culture. The study was approved by the Shanghai Pulmonary Hospital Ethics Committee and written informed consent was obtained from all patients before enrolment.

Processing

Patients enrolled underwent sputum smear examination and sputum culture in MGIT BACTEC 960 system. 27 patients were cultured positive while other 11 patients were cultured negative. Then these 27 samples had bacterial identification to exclude the non-tuberculosis mycobacteria and had Drug

Susceptibility Test (DST) of Streptomycin (Sm), Isoniazid (H), Rifampin (R), Ethambutol (E), Pyrazinamide (Z), Amikacin (Am), Capreomycin (Cm) and Ofloxacin (Ofx). The drug concentration of the medium was as follows: Sm 1.0 mg/ml, H 0.1 mg/ml, R 1.0 mg/ml, E 5.0 mg/ml, Z 100 µg/ml, Am 1.0 mg/ml, Cm 2.5 mg/ml, Ofx 2.0 mg/ml. Patients had their demography information including sex, age, medication history and drug resistance profile.

Statistical analysis

The data was analysed by software SPSS19.0. Difference between the two groups was compared by using independent-samples T-test. Categorical measurements were analysed by means of the χ^2 test or Fisher's exact test in the case of 2×2 contingency tables. We performed logistic regression analysis to explore the associations between PZA using time and the resistant to PZA outcomes. P values < 0.05 were considered statistically significant.

Results

Demographic characteristics

38 patients were randomly assigned in this trial. But 11 patients had negative sputum culture, so only 27 patients with positive culture of *M. tuberculosis* were included in the research. The demographic characteristics of these 27 patients were listed in

Table 1. All patients were HIV negative. 3 (11.1%) patients were female and the average age was 34.9 ± 10.6 (19-54) years. The average time of anti-tuberculosis treatment before enrolment was 2.6 ± 2.9 (1 month to 8.25 years) years. 20 samples were classified as MDR-TB and 7 samples were Extensively Drug-Resistant Tuberculosis (XDR-TB).

Analysis of PZAs and PZA group

Patients were divided into 2 groups according to DST results of PZA sensitivity (Table 2). 23 patients were resistant to PZA (PZA group); 4 patients were sensitive to PZA (PZAs group).

There is no significant different between the two groups in age, sex, medication history and imaging performance of cavities ($P > 0.05$). The mean time of anti-tuberculosis treatment before enrolled in the study was 2.6 ± 3.1 years in PZA group and 2.3 ± 1.4 years in PZAs group. The mean using time of PZA prior in PZA group and PZAs group was 1.1 ± 2.0 years and 0.5 ± 0.3 years respectively. 16 (80%) of MDR-TB isolates were resistant to PZA and all 7 (100%) XDR-TB isolates were resistant to PZA. Most patients had been used PZA for less than 6 months in both PZA group (16/23) and PZAs group (3/4). Logistic regression analyses showed no significant associations between PZA using time and the resistant to PZA outcomes (odds ratio=0.60, 95% confidence interval=0.11-3.50).

Table 1. Demographic characteristics, drug resistance, PZA using time and average treatment time in MDR/XDR-TB patients at the baseline.

Case no.	Gender	Age (years)	Resistant to PZA	Drug resistance profile	PZA using time (years)	Average Treatment time (years)
1	Male	50	Yes	HRE	0.58	0.58
2	Male	33	Yes	SHREOfx	1.5	2.42
3	Male	44	Yes	SHREOfx	0.17	3.5
4	Male	19	Yes	SHREOfx	0.42	1.25
5	Male	29	Yes	SHREAm	1.83	8.25
6	Male	33	Yes	SHREAmCmOfx	6	13
7	Male	47	Yes	SHREAmCmOfx	1.75	2.83
8	Male	28	Yes	SHREOfx	8.25	8.25
9	Female	21	Yes	SHROfx	0.83	2.42
10	Male	19	Yes	SHREOfx	0.42	0.75
11	Male	45	Yes	SHREOfx	0.08	0.08
12	Male	42	Yes	SHREAmCmOfx	0.17	2.17
13	Male	42	Yes	SHREAmCmOfx	0.25	3.33
14	Male	47	Yes	SHREOfx	0.5	2
15	Male	22	Yes	HRE	0.17	0.92
16	Female	24	Yes	SHREAmOfx	0.58	0.58
17	Male	52	Yes	SHREAmCmOfx	1.08	2.08

18	Female	22	Yes	SHREOfx	0.25	0.92
19	Male	27	Yes	SHREAmOfx	0.33	1.58
20	Male	35	Yes	HR	0.25	0.25
21	Male	27	Yes	SHRE	0.25	0.58
22	Male	33	Yes	SHRE	0.17	0.67
23	Male	54	Yes	HROfx	0.25	2.08
24	Male	32	No	SHR	0.33	4
25	Male	33	No	HRE	0.83	1.5
26	Male	37	No	HR	0.58	2.83
27	Male	44	No	SHR	0.25	0.75

Notes: S: Streptomycin; H: Isoniazid; R: Rifampin; E: Ethambutol; Am: Amikacin; Cm: Capreomycin; Ofx: Ofloxacin.

Table 2. Analysis of the PZAs and PZA_r group.

	PZAs group	PZA _r group	P
Patient number	4	23	
Age, y, mean	36.5 ± 5.4	34.6 ± 11.3	0.065
Sex			1
Male	4	20	
Female	0	3	
Average treatment time (years)	2.3 ± 1.4	2.6 ± 3.1	0.825
PZA using time (years)	0.5 ± 0.3	1.1 ± 2.0	0.535
≤ 6 months	3 (75%)	16 (69.6%)	
>6 M ≤ 1 y	1 (25%)	1 (4.3%)	
>1 y ≤ 5 y	0 (0%)	4 (17.4%)	
>5 y	0 (0%)	2 (8.7%)	
With cavity	4 (100%)	22 (95.7%)	1
Drug resistant to			
Ethambutol	1 (25%)	18 (78.3%)	0.065
Streptomycin	2 (50%)	19 (82.6%)	0.204
Amikacin	0 (0%)	8 (34.8%)	0.285
Capreomycin	0 (0%)	5 (21.7%)	0.561
Ofloxacin	1 (25%)	17 (73.9%)	0.093
MDR	4 (100%)	16 (69.6%)	0.545
XDR	0 (0%)	7 (30.4%)	

Discussion

The most popular accepted mechanism of pyrazinamide is that it converses into pyrazinoic acid by the bacterial pyrazinamidase enzyme then be expelled from the bacteria by an efflux pump [6]. The pyrazinoic acid is protonated in the extracellular environment and then re-enters the

mycobacterium, releasing the proton and causing a lethal disruption of the membrane [3]. So that pyrazinamide can kill semi dormant tuberculosis bacteria existing in the macrophages with acidic environments while other drugs cannot do so well there [6].

Although WHO recommends pyrazinamide to be an essential drug in the intensive phase, the recommendation is conditional and the quality of evidence is very low [4]. WHO also recommends the radiometric (Bactec 460TB) or non-radiometric (Bactec MGIT 960) liquid medium to test PZA susceptibility, with a MIC of 100 mg/l considered susceptible and otherwise resistant. Whitfield et al. [7] summarized several systematic reviews and meta-analysis to find that the PZA resistant rate increases with the resistance to other drugs. In one review, Chang et al. [8] identified 128 articles with eligible pyrazinamide susceptibility testing in *Mycobacterium tuberculosis* and the author found that the median prevalence (range) of pyrazinamide resistance was much higher in MDR tuberculosis isolates (51% (31% to 89%)) than in non-MDR isolates (5% (0% to 9%)) [8]. Astonishingly, more than 90% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide in Europe by a study of patients with MDR, pre-MDR and XDR-TB in 16 European countries [9]. A recent study indicated that non-MDR isolates had PZA resistant rate of only 11.7% (12/103) while it is 69.0% (40/58) in all the MDR isolates by gene sequencing detection [5]. This is the same in our study; the PZA resistant rate was 80% (16/20) in MDR-TB and 100% (7/7) in XDR-TB. The drug resistant prevalence in PZA_r MDR patients in this study were 82.6% (19/23) for streptomycin, 78.3% (18/23) for ethambutol, 34.8% (8/23) for amikacin, 21.7% (5/23) for capreomycin and 73.9% (17/23) for ofloxacin.

With such a high resistant rate to PZA, is this drug still effective in treating MDR-TB? The review by Ahuja et al. [10] used random effects multivariable logistic meta-regression to estimate adjusted odds of treatment success and found that treatment success, compared to failure/relapse or death, was significantly associated with the use of PZA (aOR 1.3, 95% CI 1.1-1.6). But when compared to failure or relapse, the aOR was

1.2, (95% CI 0.9-1.7), and aOR was 1.1 (95% CI 0.9-1.4) compared to failure, relapse, death or default. It showed that the association between use of PZA and treatment success was not strong in this review. But the author did not compare the treatment success between PZA resistant subjects and PZA sensitive subjects. In another review including MDR-TB and XDR-TB, PZA susceptible patients using PZA was significantly associated with treatment success (aOR 1.6, 95% CI 1.1-2.4) vs. failure or relapse, and aOR 1.4, 95% CI 1.1-1.8 vs. failure, relapse or death) [11]. In the study of Chang et al. [12] assembled a cohort of 194 patients with MDR pulmonary TB given fluoroquinolone-containing regimens. Authors suggest that pyrazinamide is very important in fluoroquinolone-based tuberculosis therapy because when combined PZA in PZA sensitive patients increases the early sputum culture conversion rate and treatment success rate of 38% for both by a best estimate. But there was also a different conclusion. Budzik et al. [13] found that treatment failure and mortality rates were non-significantly different between MDR-TB cases with PZA-resistant and PZA-susceptible MDR-TB controls (18% vs. 29%). There was no statistically significant difference between treatment failure and mortality rates in patients infected with PZA monoresistance compared to pansusceptible controls (4% vs. 8%, $p=0.51$), or those with PZA and MDR resistance compared to MDR controls (18% vs. 29%, $p=0.40$). In our study, the patients were assigned to different groups with different dose of delamanid, so the relationship between PZA susceptibility and treatment result was difficult to decide.

Are there any characteristics associated with PZA resistance in patients with MDR-TB? Budzik et al. [13] discovered that there were no significant differences in patient characteristics between PZA and MDR resistance groups and MDR groups. In our study, we calculated the previous PZA using time and the previous average anti-tuberculosis treatment time of the two groups. The mean time of anti-tuberculosis treatment was 2.6 ± 3.1 years in the PZA group and 2.3 ± 1.4 years in the PZAs group before enrolment. The mean time of using PZA in the PZA group and PZAs group were 1.1 ± 2.0 years and 0.5 ± 0.3 years respectively before enrolment. 16 (80%) of MDR-TB samples were resistant to PZA and all 7 (100%) of XDR-TB samples were resistant to PZA. But the case number was too small to give an appropriate statistical analysis to calculate the relationship between the using time and PZA resistance. Most patients (69.6%) used PZA for less than 6 months in the PZA group before enrolment. Does this mean the PZA resistant tuberculosis inclined to develop into MDR-TB? To solve this conjecture we need carefully planned cohort study with large sample sizes and long follow-up duration.

In 2014, 480 000 cases of multidrug-resistant TB estimated to have occurred, and an estimated 190 000 people died of MDR-TB. Patients with drug-resistant TB currently require a minimum of 18 to 24 months of treatment. During the long treatment period, patients have to take more than 14,000 pills of different kind and injections daily for at least 6 months in the intensive phase [14]. The long and more aggressive MDR-TB treatment brings the pain and side effects which may lower

the treatment compliance [14]. Now we have two brand-new antituberculosis drugs on the market, bedaquiline and delamanid, which have shown effectiveness in preliminary studies of shortened regimens treating MDR tuberculosis [15]. Incorporation of pyrazinamide and other newly invented drugs into a new regimen had been tested with satisfactory result. Some other new drugs are in the process of phase II or phase III clinical trials. For example, Pretomanid, a nitroimidazole new drug, when combination with moxifloxacin and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity in MDR tuberculosis during 8 weeks of treatment [16]. This new regimen may enter phase III trial to shorten and simplify treatment of drug-susceptible and MDR tuberculosis. There were also other combinations of new drugs with PZA which have showed efficacy [17]. So eventually we still depend on the trials to give us the result of the benefit to add PZA in a MDR regimen.

In conclusion, this is a descriptive essay with small sample size. We find that PZA resistant rate increases in prevalence as risk of resistance to other drugs increases. In our study, the rate of PZA resistance was 80% (16/20) in MDR-TB and 100% (7/7) in XDR-TB. The mean time of using PZA prior to the study in PZA group and PZAs group were 1.1 ± 2.0 years and 0.5 ± 0.3 years respectively. It is difficult to decide if the PZA resistance can induce more drug resistance or result in bad treatment outcome. And is it useful for MDR-TB patients to take PZA when DST showed resistant. So case control study of large sample sizes should be conducted to answer these questions.

Acknowledgments

The authors thank all the participants at Shanghai Pulmonary Hospital.

References

1. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, Wang H, Zhang W, Zhang Y. Pyrazinamide inhibits translation in *Mycobacterium tuberculosis*. *Science* 2011; 333: 1630-1632.
2. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. *Chest* 1988; 94: 845-850.
3. Zimic M, Fuentes P, Gilman RH, Gutierrez AH, Kirwan D, Sheen P. Pyrazinoic acid efflux rate in *Mycobacterium tuberculosis* is a better proxy of pyrazinamide resistance. *Tuberculosis (Edinb)* 2012; 92: 84-91.
4. WHO Guidelines approved by the guidelines review committee. World Health Organization 2011.
5. Tan Y, Hu Z, Zhang T, Cai X, Kuang H, Liu Y, Chen J, Yang F, Zhang K, Tan S, Zhao Y. Role of *pncA* and *rpsA* gene sequencing in detection of pyrazinamide resistance in *Mycobacterium tuberculosis* isolates from southern China. *J Clin Microbiol* 2014; 52: 291-297.
6. Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semidormant *Mycobacterium*

- tuberculosis bacterial populations. *Am Rev Respir Dis* 1992; 145: 1223-1225.
7. Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, van Helden PD, van Rie A. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. *PLoS One* 2015; 10: e0133869.
 8. Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in *Mycobacterium tuberculosis*: a systematic review with meta-analyses. *Antimicrob Agents Chemother* 2011; 55: 4499-4505.
 9. Gunther G, van Leth F, Altet N, Dedicoat M, Duarte R, Gualano G, Kunst H, Muylle I, Spinu V, Tiberi S, Viikklepp P, Lange C. Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. *Int J Tuberc Lung Dis* 2015; 19: 1524-1527.
 10. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, Oriordan P, Pai M, Palmero D, Park SK, Pasvol G, Pena J, Perez-Guzman C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viikklepp P, Westenhouse J, Yew WW, Yim JJ. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. *PLoS Med* 2012; 9: e1001300.
 11. Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Pena JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. *Clin Infect Dis* 2014; 59: 1364-1374.
 12. Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. *Antimicrob Agents Chemother* 2012; 56: 5465-5475.
 13. Budzik JM, Jarlsberg LG, Higashi J, Grinsdale J, Hopewell PC, Kato-Maeda M, Nahid P. Pyrazinamide resistance, *Mycobacterium tuberculosis* lineage and treatment outcomes in San Francisco, California. *PLoS One* 2014; 9: e95645.
 14. Njire M, Tan Y, Mugweru J, Wang C, Guo J. Pyrazinamide resistance in *Mycobacterium tuberculosis*: Review and update. *Adv Med Sci* 2016; 61: 63-71.
 15. Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis. a historical perspective. *Ann Am Thorac Soc* 2015; 12: 1749-1759.
 16. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. *Lancet* 2015; 385: 1738-1747.
 17. Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. *Antimicrob Agents Chemother* 2015; 59: 129-135.

***Correspondence to**

Heping Xiao

Tuberculosis Center for Diagnosis and Treatment

Shanghai Pulmonary Hospital

Tongji University School of Medicine

PR China